Moderna Circles BioNTech’s German mRNA Plants as Cost Cuts and a $1 Billion Buyback Reshape the Oncology Bet

BioNTech holds nearly EUR 17 billion in cash and securities, yet the company is shuttering factories and shedding roughly 1,860 jobs. That apparent contradiction is drawing a curious look from its former pandemic rival, Moderna. Stéphane Bancel, Moderna’s chief executive, confirmed his team is actively evaluating BioNTech’s German production sites in Idar-Oberstein, Marburg, and Tübingen, along with a plant in Singapore — all of which are being wound down as part of a sweeping efficiency drive. The program targets annual savings of EUR 500 million by 2029 and would give Moderna a ready-made mRNA manufacturing foothold in Europe without the cost of building from scratch. For BioNTech, a sale would secure a more orderly exit from vaccine-era capacity and preserve some of the jobs at risk.

The retrenchment funds a single-minded pivot: BioNTech wants to shed its pandemic-vaccine label and emerge as a mid-cap oncology pure-play. The pipeline now holds more than 25 mid- and late-stage programs, and management expects at least 15 pivotal phase 3 studies to be running by the end of 2026, focused on antibody-drug conjugates and mRNA-based immunotherapies. A concrete milestone is imminent: together with partner DualityBio, BioNTech is preparing its first oncology FDA submission for Trastuzumab Pamirtecan (BNT323/DB-1303) in recurrent endometrial cancer. The ambition for 2030 is to be a multi-product oncology company.

The financial firepower for that shift looks ample, but the runway is not endless. Last quarter, BioNTech reported revenue of just EUR 118 million and a net loss of EUR 532 million. To keep the market onside during this cash-burning transition, the company launched a $1 billion share buyback on the Nasdaq in June, with a ceiling of 25 million shares and execution delegated to an independent bank to avoid influencing the market. The program has helped stabilise the stock after a rough patch. The shares currently trade at around EUR 82.70, well above the March low of EUR 68.35, though still roughly 22% below the 52-week high. The 50-day moving average of EUR 80.57 has been breached — a bullish technical signal — and the relative strength index sits at 62.2, suggesting upward momentum without overheating. Over the past twelve months, however, the equity has shed about 9%.

Should investors sell immediately? Or is it worth buying BioNTech?

A series of high-stakes data readouts in the second half will determine whether the oncology bet gains credibility. Seven important trial results are due, including phase 3 data for Gotistobart in lung cancer and for the mRNA therapy BNT113 in head-and-neck tumours. The company has also recently launched five new registration studies for Pumitamig, a candidate targeting breast and stomach cancer, bringing the total number of registration-relevant trials to 13. With the calendar dense and the pipeline stakes rising, the next strategic update from management arrives today, followed by full second-quarter figures on August 4.

The upheaval extends beyond the balance sheet. In March, founders Ugur Sahin and Özlem Türeci announced they would vacate their board seats by the end of 2026, leaving a leadership void that the buyback is partly designed to paper over. Market observers see the repurchase as a signal of confidence during a period of deep organisational change. The restructuring and the factory closures will reshape BioNTech’s physical footprint, but the company’s true transformation will be judged by clinical results — and those are now just months away.

Ad

BioNTech Stock: New Analysis - 30 June

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | MODERNA | boerse | 69660248 |